Skip to main navigation Skip to search Skip to main content

A randomized, open-label, phase 2, multicenter trial of gemcitabine with pazopanib or gemcitabine with docetaxel in patients with advanced soft-tissue sarcoma

  • Neeta Somaiah
  • , Brian Andrew Van Tine
  • , Amy E. Wahlquist
  • , Mohammed M. Milhem
  • , Elizabeth G. Hill
  • , Elizabeth Garrett-Mayer
  • , Kent E. Armeson
  • , Scott M. Schuetze
  • , Christian F. Meyer
  • , Daniel Y. Reuben
  • , Anthony D. Elias
  • , William L. Read
  • , Sant P. Chawla
  • , Andrew S. Kraft
  • The University of Texas MD Anderson Cancer Center
  • Washington University School of Medicine in St. Louis
  • MUSC
  • University of Iowa Carver College of Medicine
  • American Society of Clinical Oncology
  • University of Michigan Medical School
  • Johns Hopkins Hospital
  • University of Colorado Comprehensive Cancer Center
  • Emory Clinic
  • Sarcoma Oncology Research Center
  • University of Arizona Cancer Center

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)894-904
Number of pages11
JournalCancer
Volume127
Issue number6
DOIs
StatePublished - Mar 15 2021

ASJC Scopus Subject Areas

  • Oncology
  • Cancer Research

Keywords

  • adverse events
  • best overall response
  • gemcitabine and pazopanib
  • soft-tissue sarcoma

Cite this